Trial results of idelalisib with bendamustine and rituximab in CLL

Acalabrutinib VS. Rituximab Combined with Idelalisib or Bendamustine for CLL - ASCO 2022Подробнее

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab ...Подробнее

ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory...Подробнее

$ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory...$

Updated analysis of Phase III trial of idelalisib combined with bendamustine and rituximab in CLLПодробнее

Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLLПодробнее

$Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL$

Idelalisib + bendamustine/rituximab (BR) bests BR alone in patients with relapsed/refractory CLLПодробнее

$Idelalisib + bendamustine/rituximab (BR) bests BR alone in patients with relapsed/refractory CLL$

Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLLПодробнее

$Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL$

Idelalisib combination therapy in relapsed or treatment-resistant CLL better than standard regimenПодробнее

Phase 1b trial of idelalisib plus chemoimmunotherapy for relapsed/refractory CLLПодробнее

$Phase 1b trial of idelalisib plus chemoimmunotherapy for relapsed/refractory CLL$

Популярное